Vertex, CRISPR Therapeutics ink deal on sickle cell gene therapy

By The Science Advisory Board staff writers

April 20, 2021 -- Vertex Pharmaceuticals and CRISPR Therapeutics have amended their collaboration agreement to develop, manufacture, and commercialize CTX001, an ex vivo CRISPR/Cas9-based gene editing therapy being developed for the treatment of sickle cell disease and transfusion-dependent beta-thalassemia.

Vertex will leverage its manufacturing, development, regulatory, and commercialization expertise and resources to maximize the potential for CTX001 in the U.S., Europe, and beyond. CRISPR Therapeutics will continue to support the development of CTX001 and invest in further development.

Under the terms of the amended agreement, Vertex will lead global development, manufacturing, and commercialization of CTX001, with support from CRISPR Therapeutics. Vertex will be responsible for 60% of program costs and will receive 60% of profits from future sales of CTX001 worldwide, a 10% increase from the previous agreement. CRISPR will be responsible for 40% of costs and will receive 40% of profits.

Additionally, CRISPR will receive a $900 million upfront payment, with potential for a $200 million payment upon the first regulatory approval of CTX001.


Copyright © 2021 scienceboard.net
 

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:



Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences



Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.